NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
57 hedge funds and large institutions have $51.5M invested in NeuBase Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 14 closing their positions.
172% more call options, than puts
Call options by funds: $508K | Put options by funds: $187K
2% more funds holding
Funds holding: 56 → 57 (+1)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
13% less capital invested
Capital invested by funds: $59.4M → $51.5M (-$7.87M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.9M |
| 2 |
GC
Greenlight Capital
New York
|
+$3.87M |
| 3 |
SCM
Sio Capital Management
New York
|
+$2.62M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.87M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.65M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.29M |
| 3 |
GCM
Glenview Capital Management
New York
|
-$739K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$703K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$694K |
NBSE Hedge Fund Activity: Q2 2021 in Review
57 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2021, worth a combined $51.5M — down 13% from $59.4M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new NBSE positions and 14 closed out — a net gain of 1 holder — while 17 added to existing stakes and 17 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $6.9M. The largest seller was BlackRock, cutting an estimated $4.65M.
- 57 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2021, up from 56 in Q1 2021.
- Funds reported $51.5M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2021, down 13% quarter-over-quarter.
- 15 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2021 and 14 closed out, a net change of +1 holder.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2021 was Point72 Asset Management, an estimated $6.9M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2021 was BlackRock, an estimated $4.65M sold.
Based on aggregated 13F filings for Q2 2021.